agenus
participate
webcast
hosted
william
blair
results
novel
pipeline
lexington
globe
newswire
agenus
nasdaq
agen
company
extensive
pipeline
checkpoint
antibodies
cell
therapy
adjuvants
vaccines
designed
activate
immune
response
cancers
infections
today
announced
david
malley
expert
gynecologic
oncology
members
agenus
management
team
participate
webcast
hosted
matt
phipps
william
blair
monday
september
et
david
malley
review
data
balstilimab
monotherapy
combination
zalifrelimab
presented
esmo
largest
clinical
trials
io
therapies
refractory
cervical
cancer
discuss
potential
proprietary
combination
members
agenus
management
team
available
discuss
next
steps
balstilimab
monotherapy
combination
zalifrelimab
well
progress
pipeline
assets
fc
enhanced
tigit
monospecific
bispecific
molecules
investors
media
general
public
access
replay
conference
agenus
website
https
agenus
agenus
company
focused
discovery
development
therapies
engage
body
immune
system
fight
cancer
company
vision
expand
patient
populations
benefiting
cancer
immunotherapy
pursuing
combination
approaches
leverage
broad
repertoire
antibody
therapeutics
adoptive
cell
therapies
agentus
therapeutics
subsidiary
proprietary
cancer
vaccine
platforms
company
equipped
suite
antibody
discovery
platforms
gmp
manufacturing
facility
capacity
support
clinical
programs
agenus
headquartered
lexington
information
please
visit
twitter
handle
information
may
important
investors
routinely
posted
website
twitter
statements
press
release
contains
statements
made
pursuant
safe
harbor
provisions
federal
securities
laws
including
statements
regarding
potential
anticipated
next
steps
agenus
balstilimab
zalifrelimab
well
rest
pipeline
assets
statements
subject
risks
uncertainties
could
cause
actual
results
differ
materially
risks
uncertainties
include
among
others
factors
described
risk
factors
section
recent
quarterly
report
form
annual
report
form
filed
securities
exchange
commission
agenus
cautions
investors
place
considerable
reliance
statements
contained
release
statements
speak
date
press
release
agenus
undertakes
obligation
update
revise
statements
extent
required
law
statements
expressly
qualified
entirety
cautionary
statement
contact
